Table 2.

Comparison between GTI and AAV-PRO questionnaire scoring

AAV-PRO	Active disease	Stable remission	P value	GTI-AIS≥10	GTI-AIS<10	P value
Organ-specific symptoms	27.50 (15.00–40.00)	30.00 (20.00–50.00)	0.297	32.5 (20.0–45.0)	30.0 (15.0–45.0)	0.760
Systemic symptoms	43.75 (14.06–60.94)	37.50 (18.75–62.50)	0.930	43.8 (18.8–62.5)	37.5 (18.8–56.3)	0.594
Treatment side effects	20.00 (10.00–30.00)	25.00 (15.00–35.00)	0.538	22.5 (15.0–35.0)	25.0 (10.0–35.0)	0.743
Social and emotional impact	35.42 (13.54–44.88)	25.00 (12.50–45.83)	0.157	37.5 (16.7–41.9)	25.0 (8.3–45.8)	0.163
Concerns about the future	45.00 (26.25–55.00)	25.00 (15.00–50.00)	0.019	40.0 (20.0–55.0)	25.0 (15.0–50.0)	0.237
Physical functioning	18.75 (6.25–37.50)	12.50 (0.00–31.25)	0.100	18.8 (6.3–48.4)	12.5 (0.0–25.0)	0.034

AAV-PRO, ANCA-associated vasculitis patient-reported outcomes; AIS, Aggregate Improvement Score; ANCA, antineutrophil cytoplasmic antibodies; GTI, Glucocorticoid Toxicity Index.